Health News Releases

  • Today July 2
February 29, 2024 15:36
Galderma Announces Record 2023 Net Sales of Over 4 B USD and Significant Core EBITDA Margin Expansion
Galderma: Delivered against full year guidance for another consecutive year with strong financial performance · Galderma achieved net sales of 4.082 B USD, up 8.5% year-on-year on a constant cur
February 29, 2024 15:25
Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas
Takeda (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2F&esheet=53901571&newsitemid=20240226565897&lan=en-US&anchor=Takeda&index=1&md5=66a3b376ad586d49f3651a4e8ba4fd
February 29, 2024 14:00
Medidata and Sanofi Vaccines Extend Collaboration to Improve Patient Centricity and Trial Efficiency
Medidata (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.medidata.com%2F&esheet=53892194&newsitemid=20240206439222&lan=en-US&anchor=Medidata&index=1&md5=ba87686335d43b4ad5753838
February 28, 2024 17:02
Galderma to Showcase Latest Updates From Its Broad, Innovative and Leading Dermatology Portfolio at the 2024 American Academy of Dermatology Annual Meeting
Galderma, the pure-play dermatology category leader, will be showcasing its latest clinical and educational efforts at the American Academy of Dermatology (AAD) Annual Meeting from March 8-12, 2024, h
February 28, 2024 12:05
ReNAgade Therapeutics Appoints Joe Bolen, Ph.D., Chief Science Innovation Officer
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Joe Bolen, Ph.D., an Executive Partner at MPM BioImpact, former Chief Scientific Officer at P
February 28, 2024 11:50
BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
BeiGene (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.beigene.com%2F&esheet=53900859&newsitemid=20240226047170&lan=en-US&anchor=BeiGene&index=1&md5=9fa7f0cbddab2bafa454d24c749
February 25, 2024 10:15
Celltrion presents new two-year data for subcutaneous infliximab (CT-P13 SC) in inflammatory bowel disease (IBD) at the 19th ECCO Congress
Celltrion today presented positive two-year results from the extended LIBERTY studies (LIBERTY-CD1 and LIBERTY-UC2) in patients with moderately to severely active Crohn’s disease (CD) and ulcerative c
Launch of New Features, discover the unique Incision Location Optimization tool on SAV-IOL Toric Cal
February 23, 2024 17:35
New Swiss Made Features for Cataract Surgery Lens Selection
The company Swiss Advanced Vision (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fsav-iol.com%2F&esheet=53899982&newsitemid=20240222791326&lan=en-US&anchor=Swiss+Advanced+Vision&ind
February 23, 2024 14:10
ReNAgade Therapeutics to Present at the Evercore ISI 2024 Emerging Biotech Conference
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Amit D. Munshi, Chief Executive Officer, will virtually present at the Evercore ISI 2024 Emer
February 22, 2024 17:20
Parse Biosciences Launches Evercode Whole Transcriptome Version 3, Boosting Usability and Performance
Parse Biosciences (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.parsebiosciences.com%2F&esheet=53898438&newsitemid=20240221815046&lan=en-US&anchor=Parse+Biosciences&index=1&md
February 22, 2024 15:35
MMI Raises $110 Million in Series C Financing
MMI (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.mmimicro.com%2F&esheet=53897487&newsitemid=20240221774903&lan=en-US&anchor=MMI&index=1&md5=d18846e1e7a7c30d597fb199c3bb2d60)
February 21, 2024 17:25
Sinovac Amends Shareholder Rights Plan
Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that its board of directors has amended its shareholder righ
software image (Graphic: Business Wire)
February 21, 2024 13:45
AI Medical Service Inc. Completes First Regulatory Review and Device Registration of Gastric AI-based Endoscopic Diagnosis Support System from Singapore’s HSA
AI MEDICAL SERVICE INC. (hereinafter AIM), a medical start-up specializing in the development of diagnostic endoscopic AI, is excited to announce the first instance of Singaporean regulatory review an
February 21, 2024 09:30
MRM Health Initiates Clinical Research in Parkinson’s Disease
MRM Health, a clinical-stage biopharmaceutical company, announced today that it has received regulatory and ethics committee approval to start an observational, cross-sectional clinical trial to study
February 20, 2024 10:10
Biocytogen and Gilead Enter Into a Multi-Target Antibody Collaboration Agreement
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announces an antibody evaluation and option agreement with Gilead Sciences, Inc. The agreement provides Gilead access t
Patient Safety Movement Foundation Outlines 2024 Action Plan for Creating a Safer Healthcare System
February 18, 2024 13:15
Patient Safety Movement Foundation Outlines 2024 Action Plan for Creating a Safer Healthcare System
At the Patient Safety Movement Foundation (https://psmf.org)’s annual Mid-Year Event on January 26, patient safety experts from around the world participated in the creation of an action plan to elimi
February 15, 2024 10:30
HistoSonics Awarded Key Position in UK’s Novel Innovation Program
HistoSonics®, (www.histosonics.com), the manufacturer of the Edison® System and novel histotripsy therapy platforms, announced today that the company’s Edison System has been selected to participate i
February 14, 2024 16:24
CORRECTING and REPLACING, Galderma Announces Regulatory Filing Acceptance for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in the U.S. and EU
Correction by Galderma: Results from the OLYMPIA program demonstrated that more than half of nemolizumab-treated patients achieved an at least four-point reduction in itch intensity, as measured by th
Newmont and Project C.U.R.E.’s partnership has created a positive economic ripple effect across 36 c
February 11, 2024 14:05
Newmont and Project C.U.R.E. - Two Decades of Partnership Delivering Global Medical Support
Newmont Corporation (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.newmont.com%2Fhome%2Fdefault.aspx&esheet=53893580&newsitemid=20240208935869&lan=en-US&anchor=Newmont+Corporat
February 11, 2024 11:15
Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=53894240&newsitemid=20240208344780&lan=en-US&anchor=TSE%3A4502%2FNYSE%
February 08, 2024 15:32
Galderma Takes the ‘Face of Cetaphil®’ to the Runway at New York Fashion Week
Cetaphil®, a leading dermatologist-recommended sensitive skincare brand, is launching a first-of-its-kind global skincare immersion. This immersion will put the sensitive skin science behind its formu
February 08, 2024 14:00
Prokarium Achieves Milestone with First Patient Dosing in PARADIGM-1 Non-Muscle Invasive Bladder Cancer Clinical Trial
Prokarium, a clinical-stage biopharmaceutical company bioengineering Living Cures through cutting-edge synthetic biology, today announces the dosing of the first patient in their PARADIGM-1 Phase I/Ib
February 07, 2024 15:12
Galderma Launches ‘NEXT’, a Ground-Breaking Trend Report That Unveils the Future of Aesthetics
Galderma, the emerging pure-play dermatology category leader, is proud to present “NEXT by Galderma.” A ground-breaking report, NEXT takes a deep-dive into the global aesthetics trends set to shape 20
February 07, 2024 11:15
Parse Biosciences Partners with INTEGRA Biosciences for Automated Single Cell Workflows
Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced it has entered into an agreement with INTEGRA Biosciences to integrate the Assist Plu
Professor Claude Wischik (Photo: Business Wire)
February 05, 2024 17:40
TauRx to Present Two-Year Data from Phase III Trial of HMTM in Alzheimer’s Disease at the AD/PD™ 2024 Conference in March
TauRx Pharmaceuticals Ltd., a global leader in Tau-based research in Alzheimer’s disease (AD), announced today that the company will present the 24-month data from its Phase III LUCIDITY trial of hydr
25 per page50 per page75 per page100 per page